Feasibility of stereotactic radiotherapy using a 1.5 T MR-linac: Multi-fraction treatment of pelvic lymph node oligometastases.

Werensteijn-Honingh AM; Kroon PS; Winkel D; Aalbers EM; van Asselen B; Bol GH; Brown KJ; Eppinga WSC; van Es CA; Glitzner M; de Groot-van Breugel EN; Hackett SL; Intven M; Kok JGM; Kontaxis C; Kotte AN; Lagendijk JJW; Philippens MEP; Tijssen RHN; Wolthaus JWH; Woodings SJ; Raaymakers BW; Jürgenliemk-Schulz IM.

doi:10.1016/j.radonc.2019.01.024

1 Feb 2019Peer-ReviewedPubMedResearch ArticleCited 105×TherapeuticQA & dosimetryRadiotherapy and oncology · 2019

Feasibility of stereotactic radiotherapy using a 1.5 T MR-linac: Multi-fraction treatment of pelvic lymph node oligometastases.

Werensteijn-Honingh AM, Kroon PS, Winkel D, Aalbers EM, van Asselen B, Bol GH (+17 more)

Read on PubMed →doi:10.1016/j.radonc.2019.01.024 →

Abstract

Online adaptive radiotherapy using the 1.5 Tesla MR-linac is feasible for SBRT (5 × 7 Gy) of pelvic lymph node oligometastases. The workflow allows full online planning based on daily anatomy. Session duration is less than 60 min. Quality assurance tests, including independent 3D dose calculations and film measurements were passed.